Companies › Pharmacosmos
3 active drug programs in 26 registered trials: 11 Phase 2, 8 Phase 4, 6 Phase 3, 1 Phase 1; Oncology, Hematology, Cardiovascular; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Trilaciclib Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor | CDK4, CDK6 | Phase 4 | Extensive-stage Small-cell Lung Cancer; Limited Stage Small Cell Lung Cancer; Osteosarcoma; Head and Neck Cancer Squamous Cell Carcinoma … | Oct 2027 |
| Ferric Derisomaltose Iron delivery via carbohydrate complex; replenishes iron stores in iron-deficiency anemia | SLC11A2 | Phase 3 | Iron Deficiency, Anaemia in Children; Chronic Heart Failure; Perioperative Anemia; Iron Deficiency Anemia … | Apr 2027 |
| SP-420 Iron chelator | – | Phase 2 | Beta Thalassemia Major Anemia | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05304442 | Ferric Derisomaltose | Phase 3 | Anemia, Iron Deficiency | Hematology | Mar 2025 |
| NCT06714383 | Trilaciclib | Phase 2 | Osteosarcoma | Oncology | Jul 2025 |
| NCT06752798 | Trilaciclib | Phase 2 | Head and Neck Cancer Squamous Cell Carcinoma | Oncology | Sep 2025 |
| NCT05714007 | Ferric Derisomaltose | Phase 4 | Perioperative Anemia | Hematology | Dec 2025 |
| NCT06929936 | Trilaciclib | Phase 2 | Non-Small Cell Lung Cancer | Oncology | May 2026 |
| NCT04913649 | Ferric Derisomaltose | Phase 4 | Iron Deficiency Anemia | Hematology | Nov 2026 |
| NCT05578326 | Trilaciclib | Phase 2 | Lung Cancer | Oncology | Dec 2026 |
| NCT05978648 | Trilaciclib | Phase 2 | Breast Neoplasms | Oncology | Dec 2026 |
| NCT06992739 | Trilaciclib | Phase 2 | NSCLC (Advanced Non-small Cell Lung Cancer) | Oncology | Mar 2027 |
| NCT05462704 | Ferric Derisomaltose | Phase 3 | Iron Deficiency Anemia | Hematology | Mar 2027 |
| NCT05179226 | Ferric Derisomaltose | Phase 3 | Iron Deficiency, Anaemia in Children | Hematology | Apr 2027 |
| NCT06898814 | Ferric Derisomaltose | Phase 4 | Hip Fracture | Hematology | Jun 2027 |
| NCT07490236 | Trilaciclib | Phase 1 | Trilaciclib | Oncology | Aug 2027 |
| NCT05971732 | Ferric Derisomaltose | Phase 4 | Heart Failure With Reduced Ejection Fraction | Cardiovascular | Aug 2027 |
| NCT05991128 | Ferric Derisomaltose | Phase 4 | Heart Failure With Preserved Ejection Fraction | Cardiovascular | Aug 2027 |
| NCT06427343 | Ferric Derisomaltose | Phase 4 | Heart Failure | Cardiovascular | Aug 2027 |
| NCT06027268 | Trilaciclib | Phase 2 | Metastatic Triple-Negative Breast Cancer | Oncology | Aug 2027 |
| NCT06699472 | Trilaciclib | Phase 2 | Ewing Sarcoma | Oncology | Sep 2027 |
| NCT05693909 | SP-420 | Phase 2 | Beta Thalassemia Major Anemia | Hematology | Oct 2027 |
| NCT07473128 | Trilaciclib | Phase 3 | Limited Stage Small Cell Lung Cancer | Oncology | Oct 2027 |
| NCT06569485 | Trilaciclib | Phase 2 | DLBCL | Oncology | Dec 2027 |
| NCT06929806 | Ferric Derisomaltose | Phase 3 | Chronic Heart Failure | Cardiovascular | Dec 2027 |
| NCT05407987 | Ferric Derisomaltose | Phase 3 | Gynecologic Cancer | Oncology | Dec 2027 |
| NCT05874401 | Trilaciclib | Phase 4 | Extensive-stage Small-cell Lung Cancer | Oncology | Feb 2028 |
| NCT05929729 | Ferric Derisomaltose | Phase 4 | IDA - Iron Deficiency Anemia | Hematology | Sep 2028 |
| NCT06698965 | Trilaciclib | Phase 2 | Lung Cancer, Small Cell | Oncology | Oct 2029 |
Servier Affaires Médicales Guangzhou Gloria Biosciences Syntrix Biosystems Geron Dizal Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.